IO Biotech Inc (IOBT)vsVertex Pharmaceuticals Inc (VRTX)
IOBT
IO Biotech Inc
$0.05
0.00%
HEALTHCARE · Cap: $2.32M
VRTX
Vertex Pharmaceuticals Inc
$446.83
+1.24%
HEALTHCARE · Cap: $107.89B
Smart Verdict
WallStSmart Research — data-driven comparison
VRTX leads profitability with a 35.5% profit margin vs 0.0%. VRTX earns a higher WallStSmart Score of 68/100 (B-).
IOBT
Avoid21
out of 100
Grade: F
VRTX
Strong Buy68
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for IOBT.
Margin of Safety
+53.1%
Fair Value
$952.53
Current Price
$446.83
$505.70 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Keeps 36 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Earnings expanding 61.4% YoY
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 22 in profit
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : IOBT
IOBT has a balanced fundamental profile.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 35.5% and operating margin at 38.1%.
Bear Case : IOBT
The primary concerns for IOBT are Revenue Growth, EPS Growth, Market Cap. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
IOBT profiles as a value stock while VRTX is a mature play — different risk/reward profiles.
IOBT carries more volatility with a beta of 0.89 — expect wider price swings.
VRTX is growing revenue faster at 7.8% — sustainability is the question.
VRTX generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (68/100 vs 21/100), backed by strong 35.5% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
IO Biotech Inc
HEALTHCARE · BIOTECHNOLOGY · USA
IO Biotech Inc. is a clinical-stage biotechnology firm focused on pioneering innovative immunotherapy solutions to bolster the immune response against cancer. Utilizing its novel immune-oncology platform, the company aims to stimulate and enhance the body’s innate defenses to target tumor cells. With a robust pipeline of therapeutic candidates progressing through clinical trials, IO Biotech is well-positioned to meet pressing unmet needs in oncology, particularly for solid tumors. The company's dedication to rigorous scientific research underscores its potential to transform the standards of cancer treatment and significantly improve patient outcomes.
Visit Website →Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?